Drug news
Levadex is filed at the FDA for Migraine
MAP Pharmaceuticals has submitted a New Drug Application (NDA) to the FDA for Levadex orally inhaled migraine drug for the potential acute treatment of migraine in adults.The submission is based on the FREEDOM-301 study see Headache. 2011 Apr;51(4):507-17. doi: 10.1111/j.1526-4610.2011.01869.x.
MAP0004, orally inhaled DHE: a randomized, controlled study in the acute treatment of migraine.
Aurora SK, Silberstein SD, Kori SH, Tepper SJ, Borland SW, Wang M, Dodick DW.
Source; Swedish Headache Center, Seattle, WA, USA. Allergan will co-market the drug in the USA with Botox for migraine.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.